PSP Research’s Praxis Precision Medicines PRAX Stock Holding History

PSP Research’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,500	Closed	-$483K	–	85
2026 Q1	$483K	Sell	1,500 -482	-24%	-$149K	0.34%	21
2025 Q4	$584K	Buy	+1,982	New	+$369K	0.51%	2

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PSP Research's PRAX Position: Q2 2026 in Review

PSP Research sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 1,500 shares — an estimated $483K sold.

PSP Research first reported a position in PRAX in Q4 2025 and held it in 2 quarters. The position peaked at $584K in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

PSP Research reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
PSP Research sold 1,500 Praxis Precision Medicines shares in Q2 2026, an estimated $483K.
PSP Research first reported a position in Praxis Precision Medicines in Q4 2025 and held it in 2 quarters.
PSP Research's Praxis Precision Medicines position peaked at $584K in Q4 2025.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.